Kim, S J <br/><br/>
Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Mar 2016 
 - 508-13 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdv596  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibiotics, Antineoplastic--adverse effects<br/>Cell Line, Tumor<br/>DNA, Viral--blood<br/>Depsipeptides--adverse effects<br/>Epstein-Barr Virus Infections--pathology<br/>Female<br/>Herpesvirus 4, Human--drug effects<br/>Histone Deacetylase Inhibitors--adverse effects<br/>Humans<br/>Lymphoma, Extranodal NK-T-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Pilot Projects<br/>Prospective Studies<br/>Virus Activation--drug effects